Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | 3ca20c1 | — |
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | y1a201m | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | Y013172 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y014181 | — |
Nop side effects or symptoms have been reported. No additional AE; HCP called to report a patient received extra doses of MMR II, VARIVAX, IPOL, and Daptacel after series completions; This spontaneous report was received from a Consumer and refers to a 7-year-old male patient. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were unknown by the reporter. On 02-APR-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), Injection, 0.5 mL (lot number Y013172 has been verified to be valid for Measles, Mumps, and Rubella [Wistar RA 27-3] Virus Vaccine, Live [M-M-R II], expiration date 31-JUL-2026), which was reconstituted with sterile diluent (BAXTER STERILE DILUENT) (expiration date, and lot number were not reported); with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection, 0.5 mL (lot number Y014181 has been verified to be valid for Varicella Virus Vaccine Live [Oka-Merck] [VARIVAX], expiration date 20-AUG-2026), which was reconstituted with sterile diluent (BAXTER STERILE DILUENT) (expiration date, and lot number were not reported); with Diphtheria vaccine toxoid (+) Pertussis vaccine acellular (+) Tetanus vaccine toxoid (DAPTACEL) (lot number reported as 3ca20c1, expiration date 28-FEB-2026; formulation not provided); and with Polio vaccine inact 3v (Vero) (IPOL) (lot number reported as y1a201m, expiration date 31-JAN-2027; formulation not reported). All doses were administered as vaccination (dose, vaccination scheme frequency, route of administration and anatomical site of injection were not provided for any of the vaccines). The patient received extra doses of all the previously reported vaccines after series completions (Extra dose administered). No side effects or symptoms have been reported and no additional adverse event was reported for the patient. No additional information provided.
Sterile diluent